Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural cytotoxicity trigger receptor 3 (NKp30), encoded by the NCR3 gene, is a pivotal activating receptor constitutively expressed on the surface of natural killer (NK) cells (UniProt P14770). It belongs to the immunoglobulin superfamily and plays a central role in the innate immune system's ability to recognize and destroy tumor-transformed and virally infected cells (PubMed 15039473). A key biochemical feature of NKp30 is its specific interaction with heparan sulfate (HS) proteoglycans and heparin-like structures on tumor cells, which act as functional ligands or co-receptors to facilitate NK cell docking and activation (PubMed 19380868). Beyond HS, NKp30 recognizes other ligands such as the tumor-associated protein B7-H6 and the nuclear protein BAG6 (BAT3). Upon ligand binding, NKp30 signals through association with ITAM-containing adapter proteins like CD3ζ and FcεRIγ, triggering degranulation and the release of pro-inflammatory cytokines (PubMed 21636664). In clinical oncology, the NKp30 pathway is often exploited by tumors through the shedding of soluble ligands or the expression of inhibitory splice variants, making it a significant target for immunotherapeutic interventions including monoclonal antibodies and CAR-NK cell therapies.
Binding of NKp30 to its ligands, such as heparan sulfate or B7-H6, induces the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) on associated adapter proteins (CD3ζ or FcεRIγ), which recruits Syk/ZAP-70 kinases to trigger NK cell degranulation and cytokine secretion.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural cytotoxicity trigger receptor 3 (NKp30) (NKp30).